Skip to main content

Enanta Pharmaceuticals Inc

ENTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001177648

No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Enanta Pharmaceuticals Inc changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of ENTA: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders181170−11
Shares18.8M19.7M+874.2K (+4.7%)
Value$1.40B$1.40B−$5.02M (−0.4%)

New holders (19)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to ENTA in Q1 2022
InstitutionSharesValue% of portfolio
Ra Capital Management, L.P.964,212$68.6M1.50%
Deep Track Capital, LP198,730$14.1M0.91%
Stonepine Capital Management, LLC119,972$8.54M3.54%
Tang Capital Management LLC100,000$7.12M1.44%
Erste Asset Management GmbH74,500$5.25M0.10%
Foresite Capital Management V, LLC42,250$3.01M1.23%
LMR Partners LLP31,604$2.25M0.03%
Foresite Capital Opportunity Management V, LLC22,750$1.62M2.27%
Algert Global LLC18,460$1.31M0.09%
Caption Management, LLC9,000$640.0K0.04%
Amalgamated Financial Corp.8,396$598.0K0.00%
Blueshift Asset Management, LLC4,878$347.0K0.03%
E Fund Management Co., Ltd.2,890$206.0K0.01%
Acuta Capital Partners, LLC2,300$164.0K0.08%
KBC Group NV1,586$113.0K0.00%
Baillie Gifford & Co318$23.0K0.00%
Meeder Asset Management Inc133$9.00K0.00%
Dark Forest Capital Management LP40$3.00K0.00%
Allworth Financial LP5$00.00%

Sold out (30)

Institutions that held Enanta Pharmaceuticals Inc at the end of Q4 2021 and filed for Q1 2022 without it.